Rapid Theraptic Scince Lab Inc - RTSL STOCK NEWS

Rapid Therapeutics Science Laboratories (OTC: RTSL) has transitioned three proprietary pharmaceutical grade patents from provisional to non-provisional status, focusing on inhalation formulations of CBD and CBG. CEO Donal R. Schmidt, Jr. anticipates FDA approval for these products via pressurized metered dose inhalers. Previously, RTSL marketed these cannabinoids but shifted its strategy towards research and regulatory approval. Further patent applications, including THC-based inhalants, are expected soon. RTSL emphasizes ongoing FDA compliance and product development, continuing its commitment to biopharmaceutical innovation.

Rapid Therapeutics Science Laboratories (OTC: RTSL) announced its S1 filing and mid-year strategy review on July 26, 2022. CEO Donal Schmidt emphasized the company's focus on pharmaceutical R&D and aerosol technology to enhance natural relief solutions. The company aims to file an investigational new drug application (IND) for its CBD metered dose inhaler (MDI) with the FDA. Despite CBD's legal status in many states, it is not FDA-approved for consumption. RTSL remains committed to research and development in biologics while seeking a major stock exchange listing.

Rapid Therapeutics Science Laboratories (OTC: RTSL) has announced its participation in the Respiratory Drug Delivery (RDD) 2022 Conference from May 1-5, 2022, in Orlando, Florida. The conference is recognized globally in the respiratory field, influencing key regulatory and scientific policies. RTSL focuses on natural relief innovations through aerosol delivery, including pressurized metered dose inhalers (pMDI) containing patent-pending cannabinoid compounds. The company is preparing to submit an investigational new drug application (IND) to the FDA for its CBD MDI.

Rapid Therapeutic Science Laboratories (OTC: RTSL) has executed a 1-for-25 reverse stock split effective March 31, 2022, to facilitate its goal of uplisting to the Nasdaq Capital Market. The common stock will initially trade under the symbol 'RTSLD' for 20 business days before reverting to 'RTSL'. Additionally, the authorized shares of common stock have been raised to 800 million. The reverse split was approved by shareholders on January 11, 2022, and aims to enhance market awareness and attract new investors. However, there are no guarantees of meeting Nasdaq's uplisting requirements.

Rapid Therapeutic Science Laboratories (OTC: RTSL) announces CEO Donal Schmidt will present at the Benzinga Global Small Cap Conference on December 8, 2021, at 12:55 PM ET. The company focuses on aerosol manufacturing for non-psychoactive cannabinoid compounds, specifically developing a metered dose inhaler (MDI) for CBD. They plan to file an IND application with the FDA. Although CBD is legal in many states, it is not yet FDA approved for consumption. Interested parties can register for the conference via the provided link.

Rapid Therapeutics Science Laboratories (OTC: RTSL) announced that CEO Donal Schmidt will present a corporate overview at the Q4 Investor Summit Conference on November 17, 2021, at 2:00 PM ET. The virtual event allows for one-on-one meetings with Mr. Schmidt. RTSL focuses on non-psychoactive cannabinoid aerosol delivery, developing pressurized metered dose inhalers with proprietary pharmaceutical-grade formulations. The company plans to file an investigational new drug application (IND) for its CBD MDI. Legal in many states, CBD is not yet FDA-approved for consumption.

Rapid Therapeutics Science Laboratories (OTC: RTSL) has announced the launch of a new facility in Addison, Texas, significantly increasing its operational capacity. The 8,566 square foot facility, leased for five years, offers over double the current space, including a filling lab adhering to ISO 13485 standards. It will enhance production capacity for metered dose inhalers (MDI) and other products. The CEO highlighted that the new facility will be more cost-effective, with rental rates 50% lower than the current location, and is expected to be operational by Q1 2022.

Rapid Therapeutic Science Laboratories (OTC: RTSL) announces the appointment of two independent directors, Dr. Henry Punzi and Justin Suggs, to its Board, fulfilling a key Nasdaq requirement for potential up-listing. CEO Donal Schmidt emphasized that their expertise in medical and practice management will enhance the Company’s governance. Dr. Punzi brings extensive clinical and research experience, while Suggs has over 27 years of professional management experience in medical processes. RTSL specializes in aerosolizing cannabinoid compounds and is preparing to file an IND for its CBD product.

Rapid Therapeutics Science Laboratories (OTC: RTSL) announces that CEO Donal Schmidt will present a corporate overview at the Benzinga Global Small Cap Conference on October 27, 2021, at 1:35 PM ET. The company specializes in aerosol manufacturing of non-psychoactive cannabinoid compounds and has developed a new method for pressurized metered dose inhalers (pMDI). RTSL is preparing to file an investigational new drug application (IND) with the FDA for its CBD MDI. The company emphasizes that its products contain zero THC and are not approved by the FDA.